Table 1.

High-risk Patient Populations in the OlympiA Trial [13].

HER2-Negative Disease	Prior Therapy	High-Risk Criteria
TNBC	Neoadjuvant	Non-pCR
	Adjuvant	≥pT2 or ≥pN1
HR-positive	Neoadjuvant	Non-pCR and CPS + EG score ≥3 *
	Adjuvant	≥4 LN+

* Refer to Jeruss et al., 2008 for CPS + EG score calculation [17]. CPS + EG, clinical stage, pathologic stage, ER status, and tumour grade; HR, hormone receptor; LN, lymph node; pCR, pathological complete response; TNBC, triple-negative breast cancer.